Goldman Sachs’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$49.4M Buy
354,500
+339,800
+2,312% +$47.6M 0.01% 1582
2025
Q4
$1.8M Buy
14,700
+700
+5% +$85.1K ﹤0.01% 4690
2025
Q3
$1.55M Buy
14,000
+5,000
+56% +$568K ﹤0.01% 4694
2025
Q2
$998K Buy
9,000
+1,000
+13% +$106K ﹤0.01% 4706
2025
Q1
$896K Sell
8,000
-34,600
-81% -$3.57M ﹤0.01% 4766
2024
Q4
$3.93M Hold
42,600
﹤0.01% 3690
2024
Q3
$3.57M Sell
42,600
-15,000
-26% -$1.14M ﹤0.01% 3651
2024
Q2
$3.95M Hold
57,600
﹤0.01% 3379
2024
Q1
$4.22M Sell
57,600
-20,800
-27% -$1.6M ﹤0.01% 3251
2023
Q4
$6.35M Sell
78,400
-14,900
-16% -$1.16M ﹤0.01% 2961
2023
Q3
$6.99M Sell
93,300
-30,400
-25% -$2.34M ﹤0.01% 2700
2023
Q2
$9.53M Sell
123,700
-56,100
-31% -$4.47M ﹤0.01% 2502
2023
Q1
$14.9M Buy
179,800
+50,200
+39% +$4.16M ﹤0.01% 2066
2022
Q4
$11.1M Buy
129,600
+99,500
+331% +$7.88M ﹤0.01% 2482
2022
Q3
$1.86M Sell
30,100
-103,500
-77% -$6.53M ﹤0.01% 4045
2022
Q2
$8.26M Sell
133,600
-51,000
-28% -$3.16M ﹤0.01% 2686
2022
Q1
$11M Sell
184,600
-11,900
-6% -$761K ﹤0.01% 2595
2021
Q4
$14.3M Buy
196,500
+10,900
+6% +$751K ﹤0.01% 2434
2021
Q3
$13M Sell
185,600
-719,900
-80% -$50.6M ﹤0.01% 2462
2021
Q2
$62.4M Buy
905,500
+366,900
+68% +$24.5M 0.01% 1078
2021
Q1
$34.8M Sell
538,600
-146,000
-21% -$9.41M 0.01% 1462
2020
Q4
$39.9M Sell
684,600
-17,500
-2% -$1.06M 0.01% 1303
2020
Q3
$44.4M Buy
702,100
+270,300
+63% +$18.7M 0.01% 1093
2020
Q2
$33.2M Buy
431,800
+135,300
+46% +$10.4M 0.01% 1281
2020
Q1
$22.2M Sell
296,500
-7,600
-2% -$525K 0.01% 1428
2019
Q4
$19.8M Sell
304,100
-230,100
-43% -$15M 0.01% 1877
2019
Q3
$33.9M Sell
534,200
-140,500
-21% -$9.18M 0.01% 1385
2019
Q2
$45.6M Buy
674,700
+114,100
+20% +$7.51M 0.01% 1198
2019
Q1
$36.4M Buy
560,600
+267,000
+91% +$17.7M 0.01% 1373
2018
Q4
$18.4M Buy
293,600
+84,200
+40% +$5.89M 0.01% 1867
2018
Q3
$16.2M Sell
209,400
-419,100
-67% -$31.7M ﹤0.01% 2083
2018
Q2
$44.5M Buy
628,500
+44,600
+8% +$3.15M 0.01% 1294
2018
Q1
$44M Sell
583,900
-408,200
-41% -$32.4M 0.01% 1284
2017
Q4
$71.1M Sell
992,100
-332,400
-25% -$25.2M 0.02% 1030
2017
Q3
$107M Buy
1,324,500
+104,500
+9% +$7.99M 0.03% 770
2017
Q2
$86.4M Buy
1,220,000
+7,400
+0.6% +$492K 0.02% 867
2017
Q1
$82.4M Sell
1,212,600
-1,028,800
-46% -$72.3M 0.02% 886
2016
Q4
$161M Buy
2,241,400
+817,000
+57% +$60.7M 0.05% 490
2016
Q3
$113M Sell
1,424,400
-500
-0% -$40.6K 0.03% 647
2016
Q2
$119M Buy
1,424,900
+235,300
+20% +$20.9M 0.04% 568
2016
Q1
$109M Sell
1,189,600
-430,900
-27% -$38.9M 0.04% 616
2015
Q4
$164M Sell
1,620,500
-575,800
-26% -$59.9M 0.05% 435
2015
Q3
$216M Buy
2,196,300
+728,000
+50% +$80.9M 0.07% 286
2015
Q2
$172M Sell
1,468,300
-27,800
-2% -$3.04M 0.05% 399
2015
Q1
$147M Buy
1,496,100
+247,500
+20% +$25.1M 0.05% 477
2014
Q4
$118M Buy
1,248,600
+317,500
+34% +$32.8M 0.04% 589
2014
Q3
$99.1M Buy
931,100
+226,800
+32% +$22.2M 0.03% 648
2014
Q2
$58.4M Sell
704,300
-974,000
-58% -$75.8M 0.02% 980
2014
Q1
$119M Buy
1,678,300
+536,600
+47% +$42.1M 0.04% 545
2013
Q4
$85.7M Buy
1,141,700
+83,700
+8% +$5.83M 0.03% 699
2013
Q3
$66.5M Buy
1,058,000
+205,700
+24% +$12.3M 0.02% 797
2013
Q2
$43.7M Buy
+852,300
New +$44.4M 0.02% 986

Other funds holding GILD

Goldman Sachs's GILD Position: Q1 2026 in Review

Goldman Sachs increased its Gilead Sciences (GILD) stake by 26% in Q1 2026, buying an estimated $324M and bringing the position to 11,065,214 shares worth $1.54B. The position accounts for 0.18% of the portfolio, ranked #93.

Goldman Sachs first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.35B in Q2 2014. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Goldman Sachs held 11,065,214 shares of Gilead Sciences worth $1.54B as of Q1 2026.
  • Goldman Sachs bought 2,312,701 Gilead Sciences shares in Q1 2026, an estimated $324M.
  • Gilead Sciences made up 0.18% of Goldman Sachs's portfolio in Q1 2026, its #93 holding.
  • Goldman Sachs first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Gilead Sciences position peaked at $2.35B in Q2 2014.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.